FDA Panel Views On PFS Endpoint For Avastin Could Impact Fate Of Other First-Line Cancer Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Panel’s rejection of Genentech sBLA for first-line breast cancer despite meeting endpoint of progression-free survival leaves Wall Street wondering if same fate will befall ImClone/Bristol’s Erbitux in colon cancer.